Search Results

You are looking at 131 - 140 of 151 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Shailender Bhatia and John A. Thompson

and renal cell carcinoma . J Clin Oncol 2008 ; 26 : 2034 – 2039 . 46 Daud AI DeConti RC Andrews S . Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma . J Clin Oncol 2008 ; 26 : 5896 – 5903

Full access

Rashmi Chugh

Receptor Therapy Targeting angiogenesis through blockade of vascular endothelial growth factor receptor (VEGFR) has been successful in improving the outcomes of patients with many malignancies, including hepatocellular carcinoma, renal cell carcinoma

Full access

David Y. Oh, Alan P. Venook and Lawrence Fong

? Until recently, only a few immune therapies for solid malignancies were FDA-approved: the cytokines IL-2 and IFN-alpha (for renal cell carcinoma and melanoma); the cell-based therapy sipuleucel-T (for prostate cancer); and the CTLA4-blocking antibody

Full access

Katherine M. Bever and Dung T. Le

microenvironment in metastatic renal cell carcinoma . Cancer Immunol Res 2015 ; 3 : 1017 – 1029 . 52. Ebert PJ Cheung J Yang Y . MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade . Immunity

Full access

Brandon A. Dyer, Dmitriy Zamarin, Ramez N. Eskandar and Jyoti M. Mayadev

-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer . Proc Natl Acad Sci U S A 2007 ; 104 : 3360 – 3365 . 31. Thompson RH Kuntz SM Leibovich BC . Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma

Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher and Jeffrey N. Weitzel

, fibromas, renal cell carcinoma, and uterine fibroids. An individual would need to exhibit 4 minor criteria, or 3 minor and 1 major, to meet testing criteria. Furthermore, if an individual meets 2 or more major criteria but does not have macrocephaly, one of

Full access

Tanya E. Keenan and Sara M. Tolaney

metastatic renal cell carcinoma: results of a randomized phase II trial . J Clin Oncol 2015 ; 33 : 1430 – 1437 . 10.1200/JCO.2014.59.0703 25452452 5. Rosenberg JE , Hoffman-Censits J , Powles T , . Atezolizumab in patients with locally advanced

Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner and Henry S. Friedman

. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma . J Clin Oncol 2006 ; 24 : 16 – 24 . 144. Willett CG

Full access

-034 CLO19-034 CLO19-034 jnccn20187169 10.6004/jnccn.2018.7169 CLO19-035: Safety Profile and Adverse Events of Sunitinib as a First-Line Treatment for Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: Pooled Analysis of Randomized Controlled Trials

Full access

breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial . Lancet Oncol 2017 ; 18 : 654 – 662 . 67. White DA Camus P Endo M . Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma . Am